Company profile: NanoSight
1.1 - Company Overview
Company description
- Provider of instruments for optical detection and real-time analysis of sub-micron particles, including NanoSight Pro, a machine learning nanoparticle analyzer enabling automated particle tracking and analysis of 10 to 1000 nm with fluorescence detection, and Smart Manager, a cloud-connected solution for continuous data analysis, improving data management and accessibility.
Products and services
- Optical Detection and Real-Time Analysis Instruments: Patent-backed optical instruments for detecting and analyzing sub-micron particles in real time, leveraging nanoparticle detection techniques to deliver precise characterization of particle size
- NanoSight Pro: Machine-learning-driven nanoparticle analyzer executing automated processing with precise particle tracking across 10–1000 nm, with fluorescence detection for labeled species, enabling accurate, real-time analysis of sub-micron particle populations
- Smart Manager: Cloud-connected digital system linking NanoSight Pro for continuous data analysis, enhancing data management and accessibility by providing cloud access to instrument-generated nanoparticle datasets.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NanoSight
Dreamweaver
HQ: United States
Website
- Description: Provider of nonwoven battery separators made from a combination of nanofibers and microfibers, enabling 300% higher power through increased electricity transmission in batteries and improving power in electric vehicles, power tools, and other high-power applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dreamweaver company profile →
Arcturus Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage mRNA medicines and vaccines, including ARCT-154, a self-amplifying mRNA COVID-19 vaccine approved for use in adults; investigational therapies ARCT-032 and LUNAR-CF for cystic fibrosis and LUNAR-OTC for ornithine transcarbamylase deficiency; and platforms STARR™ mRNA Technology and LUNAR® lipid-mediated delivery for nucleic acid drug delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arcturus Therapeutics company profile →
P2i
HQ: United Kingdom
Website
- Description: Provider of liquid-repellent nano-coating technology using a plasma process that reduces surface energy so liquids bead and roll off, helping protect devices and materials and improve product performance by protecting them from the effects of water.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full P2i company profile →
Vironova
HQ: Sweden
Website
- Description: Provider of solutions for sub-visible particle analysis, offering products and services used in the development of particles for vaccines, drug delivery and gene therapy, as well as viral safety testing and material quality control; founded in 2005 from interdisciplinary research at the Karolinska Institute in Stockholm, Sweden.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vironova company profile →
2C Tech
HQ: United States
Website
- Description: Provider of quantum dot-based nanotechnology for retinal degenerative diseases, delivering photovoltaic stimulation to the retina via intravitreal injection to activate photoreceptors, preserve or enhance vision, and potentially treat Retinitis Pigmentosa and Macular Degeneration, with neuroprotective effects on neuro-retinal cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 2C Tech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NanoSight
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NanoSight
2.2 - Growth funds investing in similar companies to NanoSight
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NanoSight
4.2 - Public trading comparable groups for NanoSight
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →